立体定向体部放疗用于寡转移性肾细胞癌的管理
该单中心回顾性分析纳入2004至2016年58例(73处病灶)原发肿瘤已切除、最多3处转移的肾细胞癌患者,评估立体定向体部放疗对转移灶的疗效与安全性。12与18个月局部控制率均为90.2%,无进展生存率分别为46.2%(95%CI 32.2-59)与35%(95%CI 21.4-48.9);异时性和单发转移预示更好无进展生存。结论认为该疗法安全且局部控制有效,但需前瞻性研究评估生存与生活质量影响。
要点
- 对原发灶已切除、寡转移(≤3处)肾细胞癌,SBRT局部控制率12与18个月均为90.2%。
- 异时性转移和单发转移与更好的无进展生存相关。
- 透明细胞癌患者SBRT前接受全身治疗与局部控制改善相关。
核心结论
- 立体定向体部放疗可视为寡转移性肾细胞癌的安全治疗方式,并能提供有效的局部控制。
- 未来仍需前瞻性研究评估其对生存和生活质量的影响。
研究设计与样本
- 回顾性分析2004至2016年接受立体定向体部放疗的58例肾细胞癌患者,共73处转移灶。
- 入组条件为最多诊断3处转移且原发肿瘤已切除。
- 毒性按不良事件通用术语标准第3版分类。
主要发现
- 全部患者均为肾细胞癌,其中透明细胞型占82.7%。
- 39处转移(53.4%)位于肺,19处(26%)位于淋巴结;骨转移占9.5%、肝转移占4.1%、肾上腺转移占6.8%。
- 中位随访16.1个月(范围3.5至157.1)。
- 12与18个月局部控制率均为90.2%。
- 12与18个月无进展生存率分别为46.2%(95%CI 32.2-59)和35%(95%CI 21.4-48.9)。
关键数值与推荐
- 单变量和多变量分析显示异时性转移和单发转移预示更好的无进展生存。
- 透明细胞癌病例中,立体定向体部放疗前接受全身治疗预示局部控制改善。
临床怎么用
- 对于原发灶已切除、转移灶不超过3处的肾细胞癌患者,可考虑立体定向体部放疗以实现局部控制。
- 选择患者时可关注转移灶数目与出现时机(单发、异时性转移预后更好)。
局限性
- 为回顾性分析,样本量58例,中位随访16.1个月。
- 原文指出需未来前瞻性研究评估对生存和生活质量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Kidney cancer has been increasing 1.7% annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.
引用
- Franzese C, Franceschini D, Di Brina L, et al. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. J Urol. 2019. PMID: 30577391. doi:10.1016/j.juro.2018.08.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。